Otsuka Applies for Abilify as Adjunctive Therapy for Depression; First Indication for Antipsychotic Drug in Japan

Otsuka Pharmaceutical announced on September 3 that it applied for an additional indication in late August for the antipsychotic drug Abilify (aripiprazole) as an adjunctive therapy for major depressive disorder (MDD). Abilify is the first antipsychotic drug to apply for...read more